MDT

96.13

-0.07%↓

A

143.79

-2.29%↓

VEEV

227.66

-3.26%↓

HQY

83.45

-2.26%↓

PHR.US

16.38

-3.99%↓

MDT

96.13

-0.07%↓

A

143.79

-2.29%↓

VEEV

227.66

-3.26%↓

HQY

83.45

-2.26%↓

PHR.US

16.38

-3.99%↓

MDT

96.13

-0.07%↓

A

143.79

-2.29%↓

VEEV

227.66

-3.26%↓

HQY

83.45

-2.26%↓

PHR.US

16.38

-3.99%↓

MDT

96.13

-0.07%↓

A

143.79

-2.29%↓

VEEV

227.66

-3.26%↓

HQY

83.45

-2.26%↓

PHR.US

16.38

-3.99%↓

MDT

96.13

-0.07%↓

A

143.79

-2.29%↓

VEEV

227.66

-3.26%↓

HQY

83.45

-2.26%↓

PHR.US

16.38

-3.99%↓

Search

CRISPR Therapeutics AG

Deschisă

SectorSănătate

55.73 2.71

Rezumat

Modificarea prețului

24h

Curent

Minim

54.1

Maxim

56.08

Indicatori cheie

By Trading Economics

Venit

102M

-106M

Vânzări

-3K

889K

Marjă de profit

-11,973.116

Angajați

393

EBITDA

101M

-101M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+24.56% upside

Dividende

By Dow Jones

Următoarele câștiguri

9 feb. 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

-380M

5.3B

Deschiderea anterioară

53.02

Închiderea anterioară

55.73

Sentimentul știrilor

By Acuity

16%

84%

31 / 370 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

CRISPR Therapeutics AG Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

12 ian. 2026, 23:54 UTC

Market Talk

CBA Could Underperform Again in 2026 -- Market Talk

12 ian. 2026, 23:48 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

12 ian. 2026, 23:48 UTC

Market Talk

Nikkei May Rise on Weaker Yen -- Market Talk

12 ian. 2026, 23:43 UTC

Market Talk

Gold Edges Lower on Likely Technical Correction -- Market Talk

12 ian. 2026, 23:18 UTC

Achiziții, Fuziuni, Preluări

Paramount Sues Warner Bros., Plans Proxy Fight. The Ellisons Aren't Giving Up. -- Barrons.com

12 ian. 2026, 21:56 UTC

Market Talk

Light & Wonder Gets Positive Outcome From Lawsuit -- Market Talk

12 ian. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

12 ian. 2026, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

12 ian. 2026, 21:50 UTC

Market Talk
Câștiguri

Auto & Transport Roundup: Market Talk

12 ian. 2026, 21:18 UTC

Market Talk

Global Equities Roundup: Market Talk

12 ian. 2026, 21:18 UTC

Market Talk

Pfizer CEO Sees Large Cash Market for Obesity Drugs -- Market Talk

12 ian. 2026, 20:54 UTC

Câștiguri

Gap, Fortinet, and More Stocks That Usually Outperform After Earnings -- Barrons.com

12 ian. 2026, 20:48 UTC

Market Talk

Oil Futures Settle Higher in Choppy Trade -- Market Talk

12 ian. 2026, 20:33 UTC

Market Talk

U.S. Natural Gas Jumps on Colder Weather Outlook -- Market Talk

12 ian. 2026, 20:18 UTC

Achiziții, Fuziuni, Preluări

Credit Agricole Sees Banco BPM Stake Helping 2025 Net by EUR200M >ACA.FR

12 ian. 2026, 20:18 UTC

Achiziții, Fuziuni, Preluări

Credit Agricole: European Central Bank Approves Crossing of 20% Threshold in Share Capital of Banco BPM

12 ian. 2026, 19:39 UTC

Market Talk

J&J CEO: Trump Pact Allows Company to Focus on Core Operations -- Market Talk

12 ian. 2026, 19:36 UTC

Market Talk

Gold and Silver Set New Records on Fed Probe -- Market Talk

12 ian. 2026, 19:36 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

12 ian. 2026, 19:33 UTC

Market Talk

Venezuela's 'Proven' Oil Reserves Raises Questions -- Market Talk

12 ian. 2026, 19:24 UTC

Achiziții, Fuziuni, Preluări

Dynavax: 'Party A' CEO Sent a Non-Binding $15/Shr Proposal on Dec. 23

12 ian. 2026, 19:22 UTC

Achiziții, Fuziuni, Preluări

Dynavax Files Tender Offer Recommendation Statement Related to Sanofi Deal, Mentions Talks With 'Party A'

12 ian. 2026, 18:21 UTC

Achiziții, Fuziuni, Preluări

Paramount Plans Proxy Fight to Push Hostile Warner Bid -- 2nd Update

12 ian. 2026, 18:20 UTC

Achiziții, Fuziuni, Preluări

This French Biotech Stock Surged 1,700% in 2025. Eli Lilly Is Taking an Interest. -- Barrons.com

12 ian. 2026, 18:19 UTC

Market Talk

Modest Canadian Economic Impact Seen from Venezuela Changes -- Market Talk

12 ian. 2026, 18:16 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Comcast Could Unlock Value With a Spinoff of NBCUniversal Assets, Analysts Say -- Market Talk

12 ian. 2026, 18:09 UTC

Market Talk

Global Equities Roundup: Market Talk

12 ian. 2026, 18:09 UTC

Market Talk

Baidu's Outlook Bodes Well For Shares -- Market Talk

12 ian. 2026, 18:01 UTC

Achiziții, Fuziuni, Preluări

QXO Is Raising Another $1.8 Billion for Its M&A War Chest -- Barrons.com

12 ian. 2026, 18:00 UTC

Market Talk

Canada's 'Breakeven' Employment Recalibrating -- Market Talk

Comparație

Modificare preț

CRISPR Therapeutics AG Așteptări

Obiectiv de preț

By TipRanks

24.56% sus

Prognoză pe 12 luni

Medie 68.88 USD  24.56%

Maxim 105 USD

Minim 40 USD

În baza a 18 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruCRISPR Therapeutics AG - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

18 ratings

11

Cumpărare

7

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

33.5 / 38.27Suport & Rezistență

Termen scurt

Very Strong Bearish Evidence

Termen mediu

Strong Bearish Evidence

Termen lung

Bearish Evidence

Sentiment

By Acuity

31 / 370 Clasament în Sănătate

Sentimentul știrilor

Evidențe foarte puternice de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre CRISPR Therapeutics AG

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, immune-oncology and autoimmune, in vivo, and type 1 diabetes. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease, and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting CD19 and CTX131 targeting CD70 for oncology and autoimmunune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and VCTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
help-icon Live chat